JGC
WHWK

J. Goldman & Co’s Whitehawk Therapeutics WHWK Stock Holding History

J. Goldman & Co’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,300
Closed -$160K – 489
2021
Q2 		$160K Buy
+6,300
New +$144K 0.01% 366

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

J. Goldman & Co's WHWK Position: Q3 2021 in Review

J. Goldman & Co sold out of Whitehawk Therapeutics (WHWK) in Q3 2021, closing a stake of 6,300 shares — an estimated $160K sold.

J. Goldman & Co first reported a position in WHWK in Q2 2021 and held it in 1 quarter. The position peaked at $160K in Q2 2021. 33 funds tracked by Wall St. Rank hold WHWK as of Q3 2021.

  • J. Goldman & Co reported no remaining Whitehawk Therapeutics position as of Q3 2021 after selling out during the quarter.
  • J. Goldman & Co sold 6,300 Whitehawk Therapeutics shares in Q3 2021, an estimated $160K.
  • J. Goldman & Co first reported a position in Whitehawk Therapeutics in Q2 2021 and held it in 1 quarter.
  • J. Goldman & Co's Whitehawk Therapeutics position peaked at $160K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2021.

Based on J. Goldman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.